Found 242 articles for: "basal cell carcinoma"
Facial Basal Cell Carcinoma in Patients Younger Than 40
May 2018 | Volume 17 | Issue 5 | Original Article | 525 | Copyright © May 2018
Introduction: The incidence of basal cell carcinoma in the population younger than 40 years is rising, and a majority of basal cell carcinomas occur on the head and neck. Our objective was to determin...
Read MoreA Retrospective Analysis of Complication Rates in Mohs Micrographic Surgery Patients With Clinically Large Tumors and Tumors With Aggressive Subclinical Extension
May 2018 | Volume 17 | Issue 5 | Original Article | 511 | Copyright © May 2018
Background: Clinically large cutaneous tumors and those with aggressive subclinical extension (ASE) often require wider margins and increased operative time during Mohs micrographic surgery (MMS). Our...
Read MoreVismodegib and the Hedgehog Pathway Inhibitors: A Historical Perspective to Current Clinical Application
May 2018 | Volume 17 | Issue 5 | Original Article | 506 | Copyright © May 2018
Vismodegib (Erivedge, Genentech-Roche) is the first in class of Hedgehog pathway inhibitors approved for treatment of metastatic basal cell carcinoma (BCC), or locally advanced BCC that has recurred a...
Read MoreDemographic and Tumor Characteristics of Patients Younger Than 50 Years With Nonmelanoma Skin Cancer Referred for Mohs Micrographic Surgery
May 2018 | Volume 17 | Issue 5 | Original Article | 499 | Copyright © May 2018
BACKGROUND: An increase in nonmelanoma skin cancer (NMSC) in younger patients has been reported. Many are treated with Mohs micrographic surgery (MMS). OBJECTIVE: Investigate patient and tumor charac...
Read MoreMulti-Center, Double-Blind, Vehicle-Controlled Clinical Trial of an Alpha and Beta Defensin-Containing Anti-Aging Skin Care Regimen With Clinical, Histopathologic, Immunohistochemical, Photographic, and Ultrasound Evaluation
April 2018 | Volume 17 | Issue 4 | Original Article | 426 | Copyright © April 2018
Background/Objectives: Anti-aging strategies utilizing stem cells are in the forefront. Alpha and beta defensins are natural immune peptides that have been shown to activate an LGR6-positive stem cell...
Read MoreReply to Letter: Effectiveness of Mohs and Close
March 2018 | Volume 17 | Issue 3 | Editorials | 368 | Copyright © March 2018
The following is a response to the Letter to the Editor by Konda, Francis, and Patel regarding the article “Mohs and Close” Technique (MCT) for selected cases to increase the efficiency of Mohs mi...
Read MoreLocally Advanced Basal Cell Carcinoma: Two Severe Case Presentations and Review
March 2018 | Volume 17 | Issue 3 | Case Reports | 358 | Copyright © March 2018
Basal cell carcinoma (BCC) is a common skin malignancy comprising 80% of non-melanoma skin cancers.1 Over 2.8 million cases are estimated to be diagnosed in the United States alone each year. Advanced...
Read MorePivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial
March 2018 | Volume 17 | Issue 3 | Original Article | 290 | Copyright © March 2018
Rosacea is a chronic dermatologic condition with limited treatment options, particularly for persistent erythema. This pivotal phase 3 study evaluated oxymetazoline, an a1A-adrenoceptor agonist, for t...
Read MoreIntralesional and Laser-Assisted 5-Fluorouracil in Dermatologic Disease: A Systematic Review
March 2018 | Volume 17 | Issue 3 | Original Article | 274 | Copyright © March 2018
INTRODUCTION: 5-fluorouracil has proven to be an effective therapy in the treatment of a variety of dermatologic conditions. Approved by the United States Food and Drug Administration for the topical ...
Read MoreIncreased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis
February 2018 | Volume 17 | Issue 2 | Original Article | 180 | Copyright © February 2018
BACKGROUND: Psoriasis (Ps) is a chronic inflammatory immune-mediated skin disease that has been identified as a risk factor for various conditions including neoplasms. OBJECTIVE: To compare prevalenc...
Read MoreVismodegib Use in Clinical Practice: Analysis of a United States Medical Claims Database
February 2018 | Volume 17 | Issue 2 | Original Article | 143 | Copyright © February 2018
BACKGROUND: Information is limited on the use of vismodegib for treatment of advanced basal cell carcinoma beyond the setting of clinical trials. OBJECTIVE: To investigate the treatment patterns and ...
Read MoreAn Elusive Amelanotic Melanoma and Review of Dermoscopic Findings
November 2017 | Volume 16 | Issue 11 | Case Reports | 1164 | Copyright © November 2017
Amelanotic melanoma (AM) is one of the great masqueraders in dermatology. It is a very difficult clinical diagnosis to make because these tumors are devoid of pigment and other clues of melanoma. T...
Read MoreManaging Seborrheic Keratoses: Evolving Strategies for Optimizing Patient Outcomes
November 2017 | Volume 16 | Issue 11 | Original Article | 1064 | Copyright © November 2017
The seborrheic keratosis is the most common benign skin tumor of middle-aged and elderly adults, affecting nearly 83 million individuals in the US alone. Although these are benign lesions, many pat...
Read MoreAn Adhesive Patch-Based Skin Biopsy Device for Molecular Diagnostics and Skin Microbiome Studies
October 2017 | Volume 16 | Issue 10 | Original Article | 979 | Copyright © October 2017
INTRODUCTION: A number of diagnoses in clinical dermatology are currently histopathologically confirmed and this image recognition–based confirmation generally requires surgical biopsies. The increa...
Read MoreDifferential Diagnosis of Seborrheic Keratosis: Clinical and Dermoscopic Features
September 2017 | Volume 16 | Issue 9 | Original Article | 835 | Copyright © September 2017
Seborrheic keratosis (SK) is a benign epidermal keratinocytic tumor that is extremely common, particularly in individuals over the age of 50. Most individuals with SK will have more than one lesion...
Read MoreAggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib
May 2017 | Volume 16 | Issue 5 | Case Reports | 508 | Copyright © May 2017
The Food and Drug Administration approved Ruxolitinib in 2011 for the treatment of primary myelofibrosis. Five-year safety data showed a higher incidence of skin cancer in patients treated with Rux...
Read MoreRadiation Therapy in Dermatology: Non-Melanoma Skin Cancer
May 2017 | Volume 16 | Issue 5 | Original Article | 464 | Copyright © May 2017
Background: Dermatologists were historically well versed in the use of radiation therapy for the management of non-melanoma skin cancers and various inflammatory dermatologic conditions. With the a...
Read MoreCurrent Perspectives Among U.S. Dermatologists on Chemoprevention of Nonmelanoma Skin Cancer: A Survey-Based Study
May 2017 | Volume 16 | Issue 5 | Original Article | 449 | Copyright © May 2017
Introduction: Nonmelanoma skin cancer (NMSC) is the most common malignancy in the US Primary prevention of NMSC with physical photoprotective measures are often not sufficient to impact skin cancer...
Read MoreSafety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest
May 2017 | Volume 16 | Issue 5 | Original Article | 438 | Copyright © May 2017
Background: Actinic keratosis (AK) can affect large skin areas. Ingenol mebutate (IngMeb) gel (0.015% and 0.05%) is approved for topical treatment of AK in a single contiguous area of ~25 cm2.
...
Read MoreAdvancing the Understanding of Seborrheic Keratosis
May 2017 | Volume 16 | Issue 5 | Original Article | 419 | Copyright © May 2017
The seborrheic keratosis, which is ubiquitous throughout all populations, is a benign tumor of the skin. Seborrheic keratosis are among the top 20 dermatologic conditions treated by dermatologists....
Read More